title: Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
authors.affiliation: Endocrine-Hypertension Research Unit, Greenslopes Hospital, Brisbane, Australia.
authors.forename: T J
authors.initials: TJ
authors.lastname: Tunny
authors.forename: M D
authors.initials: MD
authors.lastname: Ziesak
authors.forename: R
authors.initials: R
authors.lastname: Armstrong
authors.forename: S A
authors.initials: SA
authors.lastname: Klemm
authors.forename: M
authors.initials: M
authors.lastname: Stowasser
authors.forename: W L
authors.initials: WL
authors.lastname: Finn
authors.forename: R D
authors.initials: RD
authors.lastname: Gordon
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011422:Propionates / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D007189:Indans; D011422:Propionates; D009320:Atrial Natriuretic Factor; C062766:candoxatril; D015260:Neprilysin